Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus + lactobacillus acidophilus + bifidobacterium lactis + bifidobacterium longum + bifidobacterium bifidum + fructooligosaccharides
- Development stage
- Unknown
- Lead developer
- Novones
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This multi-strain synbiotic preparation is an oral live biotherapeutic product (LBP) designed for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). It consists of five specific probiotic strains—*Lactobacillus rhamnosus* FloraActive™ 19070-2, *Lactobacillus acidophilus* DSMZ 32418, *Bifidobacterium lactis* DSMZ 32269, *Bifidobacterium longum* DSMZ 32946, and *Bifidobacterium bifidum* DSMZ 32403—formulated with the prebiotic fructooligosaccharides (FOS). Developed by Novozymes, the product aims to modulate the gut microbiome to restore microbial balance, enhance intestinal barrier function, and reduce symptoms such as flatulence and irregular bowel habits. In a randomized, double-blind, placebo-controlled Phase 2 trial (NCT04206410), the synbiotic significantly improved global IBS symptoms and reduced the severity of flatulence in adult patients over an eight-week treatment period.
- Brand names
- FloraActive
- Other names
- Multi-strain synbioticLBP-IBS-D
Beyond the preview
Go deeper on lactobacillus rhamnosus + lactobacillus acidophilus + bifidobacterium lactis + bifidobacterium longum + bifidobacterium bifidum + fructooligosaccharides.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus + lactobacillus acidophilus + bifidobacterium lactis + bifidobacterium longum + bifidobacterium bifidum + fructooligosaccharides.